Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet

Topics

Biology

Biochemistry

Medicine

Immunology

Internal Medicine

Show all topics

DOI

10.1016/s0140-6736(21)01694-9